Nevertheless, the prediction accuracy of e.g. P-tau181 and P-tau217 for discriminating AD from other neurodegenerative diseases,19–21 when combined with APOE genotype, memory and executive function phenotypes, was reported to reach area under receiver operating characteristic curve (AUC) > 90% in predicting the progression from mild cognitive impairment (MCI) to AD in two relatively small samples of participants (n = 340 and 543).22 This evidence concerns the gene APOE and Alzheimer disease.